Until now, scientists have only known about the animals from fossils. But they suspected the creatures might still be alive, ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Welcome to this afternoon session with Recursion. My name is Andrew Pucher. I'm part of the Healthcare Investment Banking team, and I'm joined by Ben Taylor, CFO of Recursion; and Sara Sherman, Head ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

Ms. O’Rourke is the executive editor of The Yale Review and a professor of creative writing at Yale University. July 18, 2025 When I first told ChatGPT who I was, it sent a gushing reply: “Oh wow — it ...

A new study led by researchers at MIT titled “Your Brain on ChatGPT: Accumulation of Cognitive Debt when Using an AI Assistant for Essay Writing Task” offers a revealing window into what may happen ...

Corrected: A word was misspelled in the title of the book co-authored by Magliozzi and Peterson. The correct title is AI in the Writing Workshop: Finding the Write Balance. Since ChatGPT’s release, we ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, ...